title: Maternal and fetal outcomes of taxane chemotherapy in breast and ovarian cancer during pregnancy: case series and review of the literature.
abstract: BACKGROUND
  The purpose of this study was to evaluate the use of taxane chemotherapy during pregnancy and compare maternal and neonatal outcomes with those in women who did not receive taxanes during pregnancy, and review current existing data.
  
  
  METHODS
  This is a retrospective cohort study in which women were identified from the Cancer and Pregnancy Registry at Robert Wood Johnson Medical Center. A retrospective chart analysis and an independent t-test were carried out comparing patient outcomes. A literature search in Ovid, Medline and PubMed was then carried out using the terms 'breast or ovarian cancer', 'pregnancy', 'paclitaxel', 'docetaxel', 'taxanes' and 'chemotherapy'.
  
  
  RESULTS
  Twelve of 129 women with breast cancer were exposed to taxanes during pregnancy. Three of nine women with ovarian cancer received taxane-based treatment during pregnancy. Birth weight, gestational age at delivery, rate of growth restriction, congenital anomalies and incidence of maternal and neonatal neutropenia were not statistically different between the two groups.
  
  
  CONCLUSIONS
  Taxane-based chemotherapy does not appear to increase the risk of fetal or maternal complications when compared with conventional chemotherapy in the small cohort of women in our Registry.
authors.affiliation: Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Cooper Medical School at Rowan University, Camden. Electronic address: cardonick-elyce@cooperhealth.edu.
authors.forename: E
authors.initials: E
authors.lastname: Cardonick
authors.affiliation: Division of Hematology and Medical Oncology, Department of Medicine, Cooper Medical School at Rowan University, Camden.
authors.forename: A
authors.initials: A
authors.lastname: Bhat
authors.affiliation: Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Rochester Medical Center, Rochester, USA.
authors.forename: D
authors.initials: D
authors.lastname: Gilmandyar
authors.affiliation: Division of Hematology and Medical Oncology, Department of Medicine, Cooper Medical School at Rowan University, Camden.
authors.forename: R
authors.initials: R
authors.lastname: Somer
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001724:Birth Weight; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D001952:Bridged-Ring Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D015331:Cohort Studies; D000077143:Docetaxel; D005260:Female; D005865:Gestational Age; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality; D017239:Paclitaxel / Q000009:adverse effects / Q000627:therapeutic use; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000188:drug therapy*; D011256:Pregnancy Outcome; D012189:Retrospective Studies; D043823:Taxoids / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001952:Bridged-Ring Compounds; D043823:Taxoids; D000077143:Docetaxel; C080625:taxane; D017239:Paclitaxel